Literature DB >> 9307605

Equilibrium versus compartmental analysis for assessment of the vesicular monoamine transporter using (+)-alpha-[11C]dihydrotetrabenazine (DTBZ) and positron emission tomography.

R A Koeppe1, K A Frey, A Kume, R Albin, M R Kilbourn, D E Kuhl.   

Abstract

This work compares equilibrium to kinetic analysis of positron emission tomography data for the assessment of vesicular monoamine transporter (VMAT2) binding density using (+)-alpha-[11C]dihydrotetrabenazine ((+)-alpha-[11C]DTBZ). Studies were performed for 80 minutes after intravenous administration of 18 +/- 1 mCi (+)-alpha-[11C]DTBZ on 9 young control subjects, 20 to 45 years of age. A 9-mCi bolus was injected over the first minute of the study, whereas the remaining 9 mCi were infused at a constant rate over the following 79 minutes. Steady-state was reached in both blood and brain by approximately 30 minutes after initiation of the study. Nonlinear least-squares analysis using two- and three-compartment models, weighted integral analysis using a two-compartment configuration, and Logan plot analysis all yielded kinetic estimates of the total tissue distribution volume, DVtot(kin). These results were compared with equilibrium distribution volume estimates, DVtot(eq), calculated from the tissue to metabolite corrected arterial plasma concentration ratio after 30 minutes. Kinetic modeling results from this study were in close agreement with prior bolus-injection (+)-alpha-[11C]DTBZ studies. In the current study, coefficients of variation in DVtot(kin) (19% to 23% across regions) and DVtot(eq) (18% to 22%) were nearly identical. Equilibrium estimates of DVtot were slightly lower than kinetic estimates, averaging 5% +/- 9% lower (P = 0.04, paired t test) in regions of high binding density (caudate and putamen), but only 2% +/- 6% (P = 0.09) in lower binding density regions (cortex, thalamus, cerebellum). DVtot(eq) estimates, however, still correlated highly with DVtot(kin) estimates (r = 0.977-0.989). Steady-state conditions can be achieved in both tissue and blood by 30 minutes, and the tissue-to-blood ratios of (+)-alpha-[11C]DTBZ at equilibrium yield DVtot(eq) measures that are in close agreement with DVtot(kin) estimates. Thus, a simple, easily tolerated protocol using a loading bolus followed by continuous infusion can provide excellent measures of VMAT2 binding.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9307605     DOI: 10.1097/00004647-199709000-00001

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  30 in total

1.  Towards PET imaging of intact pancreatic beta cell mass: a transgenic strategy.

Authors:  Rebecca McGirr; Shirley Hu; Siu-Pok Yee; Michael S Kovacs; Ting-Yim Lee; Savita Dhanvantari
Journal:  Mol Imaging Biol       Date:  2011-10       Impact factor: 3.488

2.  Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease.

Authors:  Vikas Kotagal; Roger L Albin; Martijn L T M Müller; Robert A Koeppe; Kirk A Frey; Nicolaas I Bohnen
Journal:  Neurology       Date:  2014-03-28       Impact factor: 9.910

3.  Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease.

Authors:  Nicolaas I Bohnen; Martijn L T M Müller; Natalia Zarzhevsky; Robert A Koeppe; Christopher W Bogan; Michael R Kilbourn; Kirk A Frey; Roger L Albin
Journal:  Brain       Date:  2011-06-08       Impact factor: 13.501

4.  Extra-nigral pathological conditions are common in Parkinson's disease with freezing of gait: an in vivo positron emission tomography study.

Authors:  Nicolaas I Bohnen; Kirk A Frey; Stephanie Studenski; Vikas Kotagal; Robert A Koeppe; Gregory M Constantine; Peter J H Scott; Roger L Albin; Martijn L T M Müller
Journal:  Mov Disord       Date:  2014-06-07       Impact factor: 10.338

5.  Comparing fludeoxyglucose F18-PET assessment of regional cerebral glucose metabolism and [11C]dihydrotetrabenazine-PET in evaluation of early dementia and mild cognitive impairment.

Authors:  Roger L Albin; Robert A Koeppe; James F Burke; Bruno Giordani; Michael R Kilbourn; Sid Gilman; Kirk A Frey
Journal:  Arch Neurol       Date:  2010-04

6.  Striatal and Cortical β-Amyloidopathy and Cognition in Parkinson's Disease.

Authors:  Neha Shah; Kirk A Frey; Martijn L T M Müller; Myria Petrou; Vikas Kotagal; Robert A Koeppe; Peter J H Scott; Roger L Albin; Nicolaas I Bohnen
Journal:  Mov Disord       Date:  2015-09-18       Impact factor: 10.338

7.  Pattern of cardiac sympathetic denervation in idiopathic Parkinson disease studied with 11C hydroxyephedrine PET.

Authors:  Ka Kit Wong; David M Raffel; Robert A Koeppe; Kirk A Frey; Nicolaas I Bohnen; Sid Gilman
Journal:  Radiology       Date:  2012-07-27       Impact factor: 11.105

8.  Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease.

Authors:  Nicolaas I Bohnen; Martijn L T M Müller; Vikas Kotagal; Robert A Koeppe; Michael A Kilbourn; Roger L Albin; Kirk A Frey
Journal:  Brain       Date:  2010-04-22       Impact factor: 13.501

9.  Striatal [11C]dihydrotetrabenazine and [11C]methylphenidate binding in Tourette syndrome.

Authors:  R L Albin; R A Koeppe; K Wernette; W Zhuang; T Nichols; M R Kilbourn; K A Frey
Journal:  Neurology       Date:  2009-04-21       Impact factor: 9.910

10.  Cerebral amyloid deposition and serotoninergic innervation in Parkinson disease.

Authors:  Vikas Kotagal; Nicolaas I Bohnen; Martijn L T M Müller; Robert A Koeppe; Kirk A Frey; Roger L Albin
Journal:  Arch Neurol       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.